Elizabeth Nally

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

Elizabeth Nally

Nov 9, 2024, 10:21 | Blog

Toni Choueiri: Our recent perspective on the next therapies in immuno-oncology trials

Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, posted…

Nov 8, 2024, 13:58 | Blog

Rashad Nawfal: Our work on the landscape of subsequent therapies in perioperative Immuno-oncology trials

Rashad Nawfal, Postdoctoral Research Fellow at Dana Farber Cancer Institute, shared on X about recent…

Nov 6, 2024, 12:05 | Blog

Karl Semaan: Landscape of subsequent therapies in perioperative immunotherapy trials

Karl Semaan, Postdoctoral Oncology Research Fellow at Dana-Farber Cancer Institute, posted on X about recent…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023